The new three series of 98 compounds were designed having cyclopentane[b]thiophene-3-carboxamide derivatives of benzoic acid (series A), cyclopentane[b]thiophene-3-carboxylate derivatives of benzaldehyde (series B) and cyclopentane[b]thiophene-3-carboxylate derivatives of acetophenone (series C). Among all the designed derivatives, twelve compounds showed a better binding affinity with the x-ray crystallographic structure of KSP for anticancer (PDB Code: 2PG2) as compared with Raloxifene as standard drug. The compound 4 has the highest docking score with -7.037. The ADME properties were also described in the top 12 compounds. These 12 compounds can be further synthesized in the future against the anticancer cell line.